Kairos Pharma Ltd (KAPA) Stock Price, Quote & News

Company Profile

Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-smal...

Industry: Biotechnology

Sector: Healthcare

Phone: 310 948 2356

Website: kairospharma.com

Address:

2355 Westwood Blvd., Suite 139, Los Angeles, United States

Xtracked Aug. 17 at 1:13 AM

$KAPA 1:20 COMING IN SOON

0 · Reply

Xtracked Aug. 17 at 1:13 AM

$KAPA NEWS Kairos Pharma, Ltd. faces a significant risk that failure to meet NYSE American’s evolving financial, governance, and minimum price standards could trigger rapid trading suspensions or delisting. Such actions would likely erode investor confidence, materially reduce share liquidity, pressure the market price, and constrain the company’s future access to capital markets.

0 · Reply

Xtracked Aug. 13 at 4:11 AM

$KAPA How's all the quiet bag holders? Why the high volume w no movement or news?? Diluting? Either way, AQST hit, ready for much more. VELO hit, wow. MNTS is next. I recommend contacting ROSEN LAW if you were mislead by CEO and lost $. His is a PC of dog sht

0 · Reply